TNFRSF1B and adenocarcinoma: A comparison of the two groups revealed that elevated levels of TNFRII reduced the risk of subcentimetre adenocarcinoma by 89% (OR 0.11, 95% CI: 0.04‐0.30, P < .001, Table 2).